Achillion Pharmaceuticals Sets New 1-Year High at $10.24 (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) hit a new 52-week high on Monday , Analyst Ratings News reports. The company traded as high as $10.24 and last traded at $10.23, with a volume of 4,447,817 shares. The stock had previously closed at $9.76.
ACHN has been the subject of a number of recent research reports. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Thursday. They now have a $10.00 price target on the stock, up previously from $4.00. Separately, analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, August 18th. They now have a $17.00 price target on the stock, up previously from $6.00. Finally, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $9.50.
The stock’s 50-day moving average is $7.6 and its 200-day moving average is $4.81. The company’s market cap is $1.078 billion.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.69 EPS for the current fiscal year.
In other Achillion Pharmaceuticals news, major shareholder Ra Capital Management, Llc unloaded 4,235,000 shares of Achillion Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $9.53, for a total transaction of $40,359,550.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.